Q-State Biosciences has developed an all-optical electrophysiology platform for controlling and recording activity in electrically active cells: primary and human iPSC-derived cardiomyocytes and neurons.  The platform combines proprietary ultrasensitive optogenetic actuators, genetically encoded voltage indicators, stem cell technology and advanced optical imaging. 

 

Q-State Biosciences uses custom instrumentation and software to probe cellular physiology with sub-micron spatial resolution and sub-millisecond temporal resolution. 

 

Q-State technology probes dynamic cellular physiology with far higher throughput and information content than are achieved with manual patch clamp, multi electrode arrays, or calcium- or voltage-sensitive dyes.

 

Q-State provides best-in-class R&D for:

• Cardiac and neuronal drug discovery,

• Cardio- and neuro-toxicity screening,

• Mechanistic studies,

• Model development and model validation.
   

Founded in April 2013 by Harvard scientists Adam E. Cohen and Kevin Eggan, Q-State Biosciences is based in Cambridge, MA.